The studentship is available to Home/EU students where a full stipend, paid for three years at RCUK rates (for 2018/19, this is £14,777 pa) and full fees.
The following original papers underpin the therapeutic potential of isoform specific carbonic anhydrase inhibitors targeting the tumour associated isoform IX and in particular in SCLC.
1- Bryant JL, Gieling RG, Meredith SL, Allen TJ, Walker L, Telfer BA, Supuran CT, Williams KJ, White A. Novel carbonic anhydrase IX-targeted therapy enhances the anti-tumour effects of cisplatin in small cell lung cancer. Int J Cancer. 2018 Jan 1; 142(1):191-201.
2- van Kuijk SJ, Gieling RG, Niemans R, Lieuwes NG, Biemans R, Telfer BA, Haenen GR, Yaromina A, Lambin P, Dubois LJ, Williams KJ. The Sulfamate Small Molecule CA IX Inhibitor S4 Modulates Doxorubicin Efficacy. PLoS One. 2016 Aug 11; 11(8): e0161040.
3- Pettersen EO, Ebbesen P, Gieling RG, et al. Targeting tumour hypoxia to prevent cancer metastasis. From biology, biosensing and technology to drug development: the METOXIA consortium. J Enzyme Inhib Med Chem. 2015;30(5):689-721.